Tag: Robert M Davis
Merck to acquire biotech company Prometheus Biosciences for $10.8bn
Merck has agreed to acquire Prometheus Biosciences, a Nasdaq-listed clinical-stage biotechnology company, in an all-cash deal worth around $10.8 billion, in a move to bolster ... Read More
Merck to acquire Imago BioSciences to expand blood disorder drugs portfolio
Pharma giant Merck will acquire Imago BioSciences, a Nasdaq-listed clinical stage biopharmaceutical company, for a price of $36 per share in cash, which translates to ... Read More